Related Experiment Video
Updated: Aug 2, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
Clinical Guideline (CANMAT 2016) Discordance of Medications for Patients with Major Depressive Disorder in China
Yuncheng Zhu1,2,3, Zhiguo Wu4, Dongmei Zhao5
1Division of Mood Disorders, Shanghai Hongkou Mental Health Center, Shanghai, People's Republic of China.
Objective:
This survey aims to explore the current medical treatment of major depressive disorder (MDD) in China and match its degree with Canadian Network for Mood and Anxiety Treatments (CANMAT).
Methods:
A total of 3275 patients were recruited from 16 mental health centers and 16 general hospitals in China. Descriptive statistics presented the total number and percentage of drugs, as well as all kinds of treatments.
Results:
Selective serotonin reuptake inhibitors (SSRIs) accounted for the largest proportion (57.2%), followed by serotonin-noradrenaline reuptake inhibitors (SNRIs) (22.8%) and mirtazapine (7.0%) in the first therapy, while that of SNRIs (53.9%) followed by SSRIs (39.2%) and mirtazapine (9.8%) in the follow-up therapy. An average of 1.85 medications was administered to each MDD patient.
Conclusion:
SSRIs were the first choice in the first therapy, while the proportion of those drugs decreased during the follow-up therapy and were replaced by SNRIs. Plenty of combined pharmacotherapies were directly selected as the first trial of patients, which was inconsistent with guideline recommendations.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Depressive Disorders: MDD and Dysthymia
Mania and Antimanic Drugs: Overview

